Zobrazit v EDS

Liver-targeting drugs and their effect on blood glucose and hepatic lipids

Uloženo v:
Podrobná bibliografie
Název: Liver-targeting drugs and their effect on blood glucose and hepatic lipids
Autoři: Amalia Gastaldelli, Norbert Stefan, Hans-Ulrich Häring
Zdroj: Diabetologia
Diabetologia 64, 1461-1479 (2021)
Informace o vydavateli: Springer Science and Business Media LLC, 2021.
Rok vydání: 2021
Témata: Blood Glucose, 0301 basic medicine, 0303 health sciences, Receptors, Cytoplasmic and Nuclear, Farnesoid X Receptor Agonists, Fibrosis, Hepatokines, Incretins, Insulin Resistance, Non-alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, Peroxisome Proliferator-activated Receptor (ppar) Agonists, Review, Sglt2 Inhibitors, Lipid Metabolism, 3. Good health, 03 medical and health sciences, Hypoglycemic Agents/pharmacology [MeSH], Incretins/pharmacology [MeSH], Insulin resistance, Farnesoid X receptor agonists, Liver/metabolism [MeSH], Liver/drug effects [MeSH], Non-alcoholic Fatty Liver Disease/complications [MeSH], Diabetes Mellitus, Type 2/drug therapy [MeSH], Receptors, Cytoplasmic and Nuclear/metabolism [MeSH], Non-alcoholic steatohepatitis, Hypoglycemic Agents/therapeutic use [MeSH], Pharmaceutical Preparations/classification [MeSH], Incretins/therapeutic use [MeSH], Molecular Targeted Therapy/methods [MeSH], SGLT2 inhibitors, Non-alcoholic Fatty Liver Disease/drug therapy [MeSH], Diabetes Mellitus, Type 2/complications [MeSH], Humans [MeSH], Non-alcoholic Fatty Liver Disease/metabolism [MeSH], Animals [MeSH], Lipid Metabolism/drug effects [MeSH], Non-alcoholic fatty liver disease, Blood Glucose/metabolism [MeSH], Insulin Resistance/physiology [MeSH], Diabetes Mellitus, Type 2/metabolism [MeSH], Blood Glucose/drug effects [MeSH], Peroxisome proliferator-activated receptor (PPAR) agonists, Receptors, Cytoplasmic and Nuclear/agonists [MeSH], Diabetes Mellitus, Type 2, Liver, Pharmaceutical Preparations, Animals, Humans, Hypoglycemic Agents, Molecular Targeted Therapy
Popis: The global epidemic of non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) and the high prevalence among individuals with type 2 diabetes has attracted the attention of clinicians specialising in liver disorders. Many drugs are in the pipeline for the treatment of NAFLD/NASH, and several glucose-lowering drugs are now being tested specifically for the treatment of liver disease. Among these are nuclear hormone receptor agonists (e.g. peroxisome proliferator-activated receptor agonists, farnesoid X receptor agonists and liver X receptor agonists), fibroblast growth factor-19 and -21, single, dual or triple incretins, sodium–glucose cotransporter inhibitors, drugs that modulate lipid or other metabolic pathways (e.g. inhibitors of fatty acid synthase, diacylglycerol acyltransferase-1, acetyl-CoA carboxylase and 11β-hydroxysteroid dehydrogenase type-1) or drugs that target the mitochondrial pyruvate carrier. We have reviewed the metabolic effects of these drugs in relation to improvement of diabetic hyperglycaemia and fatty liver disease, as well as peripheral metabolism and insulin resistance. Graphical abstract
Druh dokumentu: Article
Other literature type
Popis souboru: application/pdf
Jazyk: English
ISSN: 1432-0428
0012-186X
DOI: 10.1007/s00125-021-05442-2
Přístupová URL adresa: https://link.springer.com/content/pdf/10.1007/s00125-021-05442-2.pdf
https://pubmed.ncbi.nlm.nih.gov/33877366
https://link.springer.com/article/10.1007/s00125-021-05442-2
https://pubmed.ncbi.nlm.nih.gov/33877366/
https://link.springer.com/content/pdf/10.1007/s00125-021-05442-2.pdf
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8187191/
https://europepmc.org/article/PMC/PMC8187191
https://push-zb.helmholtz-muenchen.de/frontdoor.php?source_opus=61827
https://repository.publisso.de/resource/frl:6451920
Rights: CC BY
Přístupové číslo: edsair.doi.dedup.....7337729e84b4e16490422453bcb1b327
Databáze: OpenAIRE
Popis
Abstrakt:The global epidemic of non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) and the high prevalence among individuals with type 2 diabetes has attracted the attention of clinicians specialising in liver disorders. Many drugs are in the pipeline for the treatment of NAFLD/NASH, and several glucose-lowering drugs are now being tested specifically for the treatment of liver disease. Among these are nuclear hormone receptor agonists (e.g. peroxisome proliferator-activated receptor agonists, farnesoid X receptor agonists and liver X receptor agonists), fibroblast growth factor-19 and -21, single, dual or triple incretins, sodium–glucose cotransporter inhibitors, drugs that modulate lipid or other metabolic pathways (e.g. inhibitors of fatty acid synthase, diacylglycerol acyltransferase-1, acetyl-CoA carboxylase and 11β-hydroxysteroid dehydrogenase type-1) or drugs that target the mitochondrial pyruvate carrier. We have reviewed the metabolic effects of these drugs in relation to improvement of diabetic hyperglycaemia and fatty liver disease, as well as peripheral metabolism and insulin resistance. Graphical abstract
ISSN:14320428
0012186X
DOI:10.1007/s00125-021-05442-2